Continue active refreshing of this index's data?
Continue active refreshing of this index's data?
About 63 results found
The STOXX® Thematic Indices family is expanding to incorporate another technology-based megatrend with a compelling growth profile.
As part of the expanding STOXX thematic offering, we are excited to introduce a new index tracking four technologies transforming business globally.
STOXX has licensed the iSTOXX Developed Markets B.R.AI.N. Index to the Canadian Coin Capital Investment Management Inc (Coincapital).
Global stocks posted a gain in May, even as emerging markets were engulfed in volatility and political developments in Italy triggered losses in Europe in the second part of the month.
Stocks rebounded in April, paring more than half of the losses from the previous two months, amid stronger-than-expected economic and earnings data, and an easing of geopolitical tensions.
This year STOXX Ltd. introduced two indices that give exposure to the growing theme of artificial intelligence (AI).
STOXX Ltd. has licensed the STOXX® Global Electric Vehicles & Driving Technology Index to BlackRock to serve as an underlying for an ETF.
Recently, the world’s largest asset managers of index-based funds have stepped up their stewardship role, pledging more active participation to assure that board decisions are aligned with ESG principles.
As we reviewed the outlook for equity markets in 2018 in a recent article, UBS highlighted the disruptive trends of digitalization and robotics in its forecast, pointing out that technology stocks may continue their march higher.
After a bumper year for equities, strategists are forecasting further gains for 2018, while pointing to risks from rising bond yields and higher volatility.
Despite the Fed’s and the ECB’s divergent trajectories, the dollar fell against the euro to $1.18 in December from $1.05 in January, confounding expectations. At the start of 2017, the average forecast from five banks pointed to the euro ending the year at $1.05.
Whether it's optimizers of patient treatment or hybrid bio-chemical drugs, many health-care stocks are inventing the future.
